Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for ICI-Induced Colitis (iCaD)
NCT05947669Phase 3Recruiting
- Sponsor
- University Hospital Odense
- Start
- Aug 2023
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of infliximab in Colitis, sponsored by University Hospital Odense. Started Aug 2023; status: recruiting.
02
Drugs
infliximab
03
Conditions
Colitis
Beyond the preview
Go deeper on NCT05947669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947669.